Hipotiroidismo central y dislipemia mixta secundarios a tratamiento con bexaroteno

Bexarotene is a synthetic retinoid analogue that joints selectively to retinoid X receptor and has been designed for treatment of advanced stages of cutaneous T- cell lymphoma. Up to a 40% of patients treated with bexarotene develop central hypothyroidism while severe mixed dyslipidemia may be present in up to 70%. We report 3 patients that developed central hypothyroidism and dyslipidemia after bexarotene treatment was initiated. In one of them, we observed normalization of the thyroid function when bexarotene treatment was stopped.